Active Stocks in Focus: Baidu, Inc. (NASDAQ:BIDU), Intersect ENT, Inc. (NASDAQ:XENT), ImmuCell Corp. (NASDAQ:ICCC)

The leading Chinese language Internet search provider, Baidu, Inc. (NASDAQ:BIDU) released that it will report its financial results for the second quarter ended June 30, 2015, after the U.S. market closes on July 27, 2015. Baidu’s management will hold an earnings conference call at 8:00 PM on July 27, 2015, U.S. Eastern Time (8:00 AM on July 28, 2015, Beijing/Hong Kong Time). Baidu, Inc. (NASDAQ:BIDU) stock hit highest price at $183.37, beginning with a price of $179.53 to finish at 187.54 by a decrease of -0.79% with a day range of $178.81-$183.37. The total market capitalization remained 63.93 Billion, total volume of 6.23 Million shares held in the session was surprisingly higher than its average volume of 3214.12 shares.

Intersect ENT, Inc. (NASDAQ:XENT) releaesed that enrollment of the first patient in the co’s pivotal study of its latest bioabsorbable steroid releasing sinus implant, currently called NOVA. NOVA is designed to mechanically prop sinuses open while delivering anti-inflammatory medication following surgical interventions such as sinus surgery in the operating room or in-office sinus dilation. Shares of Intersect ENT, Inc. (NASDAQ:XENT) opened at $28.770 with 27.75 million outstanding shares and hit to its highest price of $28.920 during the day and finally closed at $28.95 by scoring 0.84%. In the whole session, it traded on volume of 395007 shares, which turned higher than its average volume.

ImmuCell Corp. (NASDAQ:ICCC) released that an improvement in its product sales estimate outlook for second quarter to a surge in the range of 25% to 30% YoY, from the previously announced anticipated decrease in the range of 15% to 20% (no estimates). “This increase in guidance is due primarily to a better-than-expected inventory production schedule allowing us to address a portion of the pent-up demand that is building for First Defense. Despite shipping all the First Defense that we can produce, we still have a backlog of orders waiting to be shipped aggregating $1.45 million as of June 30, 2015 (as compared to $1.28 million as of March 31, 2015). We remain on track to complete all of our planned manufacturing capacity expansion investments by the first quarter of 2016.On the other consideration, ImmuCell Corp. (NASDAQ:ICCC) begun last trade with a price of $8.25 and throughout the trading session climbed at $8.99. The day-trade ended with a decrease of -1.56% to finish at $7.83.